Supriya Lifescience
NSEI:SUPRIYA Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
WA
Consensus Narrative from 1 Analyst
Expansion Into High-Margin Therapeutic Segments Like Anti-Stimulants Will Strengthen Future Prospects
Key Takeaways Expanding into high-margin therapeutic segments and increasing exports highlight Supriya Lifescience's potential for robust future revenue growth. Expanding production capacity and adopting cost-efficient strategies boost revenue opportunities and improve supply chain resilience.
View narrative₹740.00
FV
13.5% undervalued intrinsic discount20.76%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
10 days ago author updated this narrative